Innovative enterprise platform for clinical cross-omics now also accessible via high-performance cloud computing services Microsoft Azure and Amazon Web Services
December 20, 2017
Genedata, a leading provider of advanced software solutions for biopharmaceutical research and development (R&D), today announced that Genedata Profiler™, its leading enterprise software platform for omics-based profiling of patients in translational and clinical research, can now also be deployed in cloud environments such as Microsoft Azure (MS Azure) and Amazon Web Services (AWS), additional to on-premises and private cloud environments. This addresses the rapidly increasing demand from translational and clinical research groups that lack in-house IT support and need fast access to a fully integrated data platform.
Genedata Profiler enables the processing, management and analysis of massive amounts of globally distributed raw genomic, transcriptomic, metabolomic and proteomic data from technologies such as next-generation sequencing, microarray and real time-PCR, in conjunction with clinical and other phenotypic data. The enterprise architecture of Genedata Profiler facilitates access to the data and analysis algorithms by team members located at different sites, thus driving harmonization of processes across an organization. Deployment in high-performance clouds allows Genedata Profiler to offer a highly flexible and elastic solution to its clients, who enjoy the “compute on demand” benefit of booking more computing power instantaneously to deal with rapidly expanding data processing demands.
Genedata has now successfully deployed Genedata Profiler in advanced cloud settings for several biopharma clients headquartered in Europe and the USA, with globally distributed research teams. With servers, storage, networking, and virtualization managed by the cloud hosts, and Genedata taking care of the application software, the research organization is free to focus on its core competencies: processing and analyzing its research trial data through workflows in Genedata Profiler to identify biomarkers crucial for the precise targeting of its therapy under investigation.
"With its highly scalable software architecture, Genedata has been at the forefront of the management, processing, and analysis of big scientific data sets for many years," commented Dr Othmar Pfannes, CEO of Genedata. "Now with Genedata Profiler accessible on high-performance cloud platforms like AWS and MS Azure as well as on-premises, we offer even more flexibility and convenience to our clients working on tasks like biomarker discovery for clinical development in therapeutic areas such as immuno-oncology, neurology and cardiovascular disease."